DOI: https://doi.org/10.24959/cphj.19.1488

The dynamics of the antidepressant effect of atristamine in the repeated dose study

I. M. Podolsky

Abstract


Taking into account the peculiarities of the clinical application of antidepressants, namely gradual development of a therapeutically significant effect and a considerable duration of courses of treatment, an important aspect of the experimental study of promising antidepressants is the study of their antidepressant effect in the dynamics in the repeated dose studies.

Aim. To study experimentally the dynamics of the antidepressant effect of a promising antidepressant atristamine using the repeated dose design of the experiment.

Materials and methods. The tail suspension test was chosen in order to study the dynamics of development of the atristamine antidepressant effect. Atristamine (100 mg/kg/day) and isotonic solution (control group) was injected for 14 days. The studies of depressive behaviour of animals were performed on days 1, 4, 7, 10 and 14 of the experiment.

Results. The total immobility time of mice, which in the tail suspension test was the main marker of the antidepressant activity, in the group of atristamine was practically the same as that in the intact control group on the first day of the study (1 hour after single administration). On day 4 of the study, the total immobility time of the animals in the atristamine group was significantly shorter (–26.9 %) than in the intact control group. The latency to the first immobility episode of animals receiving atristamine compared to those of the intact control group was 77 % longer. On day 7 of the study, the immobility time of the atristamine group animals was shorter by 30.2 %, the latency to the first immobility episode increased by 88.2 %, and the average duration of one episode of immobility reduced by 43.5 %. On days 10 and 14 of the experiment, the results of the tail suspension test in the atristamine group confirmed further enhancement of the antidepressant effect of the test compound. The antidepressant activity was 38.4 % and 37.7 %, respectively.

Conclusions. There were no significant changes in the main markers of the antidepressant effect in the group of animals receiving atristamine after single administration. This fact can be explained by the effects of pharmacokinetic or pharmacogenetic factors. The analysis of the results in the subsequent periods of the experiment showed that the antidepressant effect of atristamine reached a reliable level on day 4 and continued to increase, on day 7 it achieved the maximum level by all markers of the tail suspension test and remained at this level to the end of the experiment.

Keywords


2-methyl-3-(phenylaminomethyl)-1H-quinolin-4-one; atristamine; antidepressant effect; tail suspension test; repeated dose study

References


Shtrygol’, S. Iu., Zubkov, V. A., Podol’skiĭ, I. N., Gritsenko, I.S. (2012). Eksperimental’naia i klinicheskaia farmakologiia, 75 (4), 7-9.

Podolsky, I. M., Shtrygol’, S. Yu., Zubkov, V. O. (2018). The psycho- and neurotropic profiling of novel 3-(N-R,R’-aminomethyl)-2-methyl-1H-quinolin-4-ones in vivo. Saudi Pharmaceutical Journal, 26 (1), 107-114. https://doi.org/10.1016/j.jsps.2017.10.005

Shtrygol’, S. Ju., Zubkov, V. O., Gritsenko, I. S., Podolsky, I. M., Shatilov, O. V. (2010). Klìnìčna farmacìâ, 14 (1), 35-38.

Podolsky, I. M., Shtrygol, S. Yu. (2016). Klìnìčna farmacìâ, 20 (4), 46-51. https://doi.org/10.24959/cphj.16.1408

Podolsky, I. M., Shtrygol, S. Yu. (2015). Neuroprotective activity of 2-methyl-3-phenylaminomethylquinolin-4-one in experimental traumatic brain injury in rats. Journal of Chemical and Pharmaceutical Research, 7 (4), 518-524.

Podolsky, I. M., Shtrygol’, S. Yu., Ostashko, V. F., Bezditko, N. V. (2013). Ukraïns’kij bìofarmacevtičnij žurnal, 2 (25), 46-49.

Shtrygol’, S. Yu., Podolsky, I. M., Zubkov, V. O., Gritsenko, I.S. (2013). Zastosuvannia 2-metyl-3-fenilaminometylkhinolin-4-onu yak zasobu antyhipoksychnoi, aktoprotektornoi ta antyalkoholnoi dii. Patent UA 102900 na vynakhid, МПК (2013.01) A61K 31/47 (2006.01), C07D 215/233 (2006.01), C07D 215/12 (2006.01), А61Р 25/00, А61Р 25/32 (2006.01). № а 2011 13575; declared 18.11.2011; published 27.08.2013, № 16, 4.

Podolsky, I., Shtrygol’, S. (2017). The analgesic properties of a promising antidepressant – 2-methyl-3-(phenylaminomethyl)-1H-quinolin-4-one. The Pharma Innovation Journal, 6 (8C), 156-160.

Podolsky, I. M., Shtrygol’, S. Yu., Tsyvunin, V. V. (2018). Klìnìčna farmacìâ, 22 (4), 34-41. https://doi.org/10.24959/cphj.18.1471

Witkin, J. M., Knutson, D. E., Rodriguez, G. J., Shi, S. (2018). Rapid-Acting Antidepressants. Current Pharmaceutical Design, 24, 1-8. https://doi.org/10.2174/1381612824666180730104707

Read, J., Gee, A., Diggle, J., Butler, H. (2019). Staying on, and coming off, antidepressants: The experiences of 752 UK adults. Addictive Behaviors, 88, 82-85. https://doi.org/10.1016/j.addbeh.2018.08.021

Council Directive 2010/63/EU of 22 September 2010 on the protection of animals used for scientific purposes (2010). Official Journal of the European Communities, L 276, 33-79.

Deacon, R. M. (2006). Housing, husbandry and handling of rodents for behavioral experiments. Nature Protocols, 1(2), 936-946. https://doi.org/10.1038/nprot.2006.120

Zubkov, V. A., Gritsenko, I. S., Taran, S. G., Podolsky, I. N., Kamenetska, O. L. (2005). Zhurnal organichnoi ta farmatsevtichnoi khimii, 3(2), 23-27.

Steru, L., Chermat, R., Thierry, B., Simon, P. (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl), 85, 367-370.

Rebrova, O. Yu. (2006). Statisticheskiy analiz meditsinskih dannyih. Primenenie paketa prikladnyih programm STATISTICA. Moscow: Mediasfera, 312.

Lad, H. V., Liu, L., Payá-Cano, J. L., Fernandes, C., Schalkwyk, L. C. (2007). Quantitative traits for the tail suspension test: Automation, optimization, and BXD RI mapping. Mammalian Genome, 18(6-7), 482-491. https://doi.org/10.1007/s00335-007-9029-1

Carlson, D., David, L. K., Gallagher, N. M., Vu, M.-A. T., Shirley, M., …, Dzirasa, K. (2017). Dynamically Timed Stimulation of Corticolimbic Circuitry Activates a Stress-Compensatory Pathway. Biological Psychiatry, 82(12), 904-913. https://doi.org/10.1016/j.biopsych.2017.06.008

Castagné, V., Porsolt, R. D., Moser, P. (2009). Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse. European Journal of Pharmacology, 616(1), P. 128-133. https://doi.org/10.1016/j.ejphar.2009.06.018


GOST Style Citations


1. 2-Метил-3-фениламинометилхинолин-4-он – потенциальный антидепрессант с ноотропными свойствами / С. Ю. Штрыголь, В. А. Зубков, И. Н. Подольский, И. С. Гриценко // Экспериментальная и клиническая фармакол. – 2012. – Т. 75, № 4. – С. 7-9.

2. Podolsky, I. M. The psycho- and neurotropic profiling of novel 3-(N-R,R’-aminomethyl)-2-methyl-1H-quinolin-4-ones in vivo / I. M. Podolsky, S. Yu. Shtrygol’, V. O. Zubkov // Saudi Pharmac. J. – 2018. – Vol. 26, Issue 1. – P. 107-114. https://doi.org/10.1016/j.jsps.2017.10.005

3. Скринінгові дослідження 3-амінометил-2-метилхінолін-4-онів як потенційних психотропних засобів / С. Ю. Штриголь, В. О. Зубков, І. С. Гриценко та ін. // Клінічна фармація. – 2010. – Т. 14, № 1. – С. 35-38.

4. Подольський, І. М. Дозозалежність ефектів перспективного антидепресанта з ноотропними властивостями 2-метил-3-(феніламінометил)-1H-хінолін-4-ону / І. М. Подольський, С. Ю. Штриголь // Клінічна фармація. – 2016. – Т. 20, № 4. – С. 46-51. https://doi.org/10.24959/cphj.16.1408

5. Podolsky, I. M. Neuroprotective activity of 2-methyl-3-phenylamino­methylquinolin-4-one in experimental traumatic brain injury in rats / I. M. Podolsky, S. Yu. Shtrygol // J. of Chemical and Pharmac. Res. – 2015. – Vol. 7, Issue 4. – P. 518-524.

6. Антигіпоксична активність 2-метил-3-феніламінометилхінолін-4-ону – перспективного антидепресанта з ноотропними властивостями / І. М. Подольський, С. Ю. Штриголь, В. Ф. Осташко, Н. В. Бездітко // Укр. біофармац. журн. – 2013. – № 2 (25). – С. 46-49.

7. Застосування 2-метил-3-феніламінометилхінолін-4-ону як засобу антигіпоксичної, актопротекторної та антиалкогольної дії. Пат. UA 102900 на винахід, МПК (2013.01) A61K 31/47 (2006.01), C07D 215/233 (2006.01), C07D 215/12 (2006.01), А61Р 25/00, А61Р 25/32 (2006.01) / Штриголь С. Ю., Подольський І. М., Зубков В. О., Гриценко І. С. – № а 2011 13575; заявл.: 18.11.2011; опубл.: 27.08.2013. – Бюл. № 16. – 4 с.

8. Podolsky, I. The analgesic properties of a promising antidepressant – 2-methyl-3-(phenylaminomethyl)-1H-quinolin-4-one / I. Podolsky, S. Shtrygol’ // The Pharma Innovation J. – 2017. – Vol. 6, Issue 8 (C). – P. 156-160.

9. Подольський, І. М. Варіативність впливу атристаміну та іміпраміну на депресивну поведінку мишей в аспекті циркадіанних чинників / І. М. Подольський, С. Ю. Штриголь, В. В. Цивунін // Клінічна фармація. – 2018. – Т. 22, № 4 – С. 34-41. https://doi.org/10.24959/cphj.18.1471

10. Rapid-Acting Antidepressants / J. M. Witkin, D. E. Knutson, G. J. Rodriguez, S. Shi // Current Pharmac. Design. – 2018. – Issue 24. – P. 1-8. https://doi.org/10.2174/1381612824666180730104707

11. Staying on, and coming off, antidepressants: The experiences of 752 UK adults / J. Read, A. Gee, J. Diggle, H. Butler // Addictive Behaviors. – 2019. – Vol. 88. – P. 82-85. https://doi.org/10.1016/j.addbeh.2018.08.021

12. Council Directive 2010/63/EU of 22 September 2010 on the protection of animals used for scientific purposes // Official J. of the European Communities. – 2010. – L 276. – P. 33-79.

13. Deacon, R. M. Housing, husbandry and handling of rodents for behavioral experiments / R. M. Deacon // Nature Protocols. – 2006. – Vol. 1(2). – P. 936-946. https://doi.org/10.1038/nprot.2006.120

14.-Диметиламинометил-2-метил-1Н-хинолин-4-он – эффективный реагент в синтезе 3-аминометилзамещенных хинолонов / В. А. Зубков, И. С. Гриценко, С. Г. Таран та ін. // Журн. орг. та фармац. хімії. – 2005. – Т. 3, № 2 (10). – С. 23-27.

15. The tail suspension test: a new method for screening antidepressants in mice / L. Steru, R. Chermat, B. Thierry, P. Simon // Psychopharmacol. (Berl). – 1985. – Vol. 85. – P. 367-370.

16. Реброва О. Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTIСA. – М.: Медиасфера, 2006. – 312 с.

17. Quantitative traits for the tail suspension test: Automation, optimization, and BXD RI mapping / H. V. Lad, L. Liu, J. L. Payá-Cano et al. // Mammalian Genome. – 2007. – Vol. 18, Issue 6-7. – P. 482-491. https://doi.org/10.1007/s00335-007-9029-1

18. Dynamically Timed Stimulation of Corticolimbic Circuitry Activates a Stress-Compensatory Pathway / D. Carlson, L. K. David, N. M. Gallagher et al. // Biol. Psychiatry. – 2017. – Vol. 82, Issue 12. – P. 904-913. https://doi.org/10.1016/j.biopsych.2017.06.008

19. Castagné, V. Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse / V. Castagné, R. D. Porsolt, P. Moser // Eur. J. of Pharmacol. – 2009. – Vol. 616, Issue 1. – P. 128-133. https://doi.org/10.1016/j.ejphar.2009.06.018




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Klìn. farm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)